# Krascendo 2 (NCT06793215)

> A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06793215
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer
- Interventions: Divarasib; Pembrolizumab; Pemetrexed; Carboplatin; Cisplatin
- Enrollment: 600
- Primary outcome: Progression-Free Survival (PFS)
- Primary outcome: Overall Survival (OS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=krascendo-2-nct06793215